{
  "docId": "019de072-a7a0-747e-aa25-0c712080af8d",
  "docSlug": "2284d180d89eee1cbed73b6e3ca03fc3",
  "documentTitle": "BioAtla | Results Presentation Deck | 9 slides",
  "authorId": "bioatla",
  "authorName": "BioAtla",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 8,
  "pageCount": 9,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 12,
  "notes": "Includes specific AE breakdown for Constipation, Peripheral Neuropathy, and Diarrhea.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-a7a0-747e-aa25-0c712080af8d/8",
  "deckHref": "/decks/019de072-a7a0-747e-aa25-0c712080af8d",
  "deckJsonHref": "/decks/019de072-a7a0-747e-aa25-0c712080af8d.json",
  "deckAnchorHref": "/decks/019de072-a7a0-747e-aa25-0c712080af8d#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.35,
        "x": 0.57,
        "y": 0.65
      },
      "kind": "callout",
      "text": "No clinically meaningful on-target toxicity observed over background. Differentiated profile due to advantageous pharmacokinetic characteristics of CAB ADCs",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e8b0a700-9153-4784-b81b-c8633e4d1d01",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.35,
        "x": 0.57,
        "y": 0.28
      },
      "kind": "chart",
      "text": "Mecbo - BA3011: Constipation (Grade 1-2 18%, Grade 3-4 0%), Peripheral Neuropathy (All Grade 1-2 23%), Diarrhea (Grade 1-2 19%, Grade 3-4 0%)",
      "attrs": null,
      "subkind": "bar-horizontal",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f21797db-2e3b-4f9a-95af-ada38b2f00a9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.35,
        "x": 0.1,
        "y": 0.18
      },
      "kind": "paragraph",
      "text": "PHASE 2 AEs Overview: AEs consistent with MMAE-based toxicity, including: Reversible myelosuppression, Transient liver enzyme elevation, Metabolic disturbances. Few related SAEs. Few related AEs leading to treatment discontinuation.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bb906fa9-9449-41c1-88e2-a7cb1f9a0364",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.03,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Note: CTCAE: Common Terminology Criteria for Adverse Events... Interim data- Data cut-off of March 31, 2022",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1a24f2cf-3fce-481a-aa6a-d9c2e70b4532",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.4,
        "x": 0.07,
        "y": 0.64
      },
      "kind": "table",
      "text": "Characteristic | BA3011 (N=68) | Any Adverse Events (AEs) 61 (90%) | Related AEs with CTCAE Grade 3 or 4 16 (23%) | Any related serious AEs 6 (9%) | Related AEs leading to death 0 | Related AEs leading to treatment discontinuation 2 (3%)",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "33a57909-f8db-4f27-bc9b-b5a7a147f8ab",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "Continued Promising Safety and Tolerability Profile in Phase 2 at the RP2D",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "934489a3-01e1-404f-949c-88aaba552e60",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "e202beff-b4d2-4e31-a6c5-7156b9472554",
      "evidence": "table/data: Characteristic | BA3011 (N=68) | Any Adverse Events (AEs) 61 (90%) | Related AEs with CTCAE Grade 3 or 4 16 (23%) | Any related serious AEs 6 (9%) | Related AEs leading to death 0 | Related AEs leading to tre",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}